SKYCellflu Quadrivalent prefilled syringe (Influenza Vaccine), the first cell culture-based quadrivalent influenza vaccine in the world, a vaccine for intramuscular injection, is a subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line.
A major advantage of cell culture technology includes the potential for a faster start-up of the vaccine manufacturing process in the event of a pandemic. The cells used to manufacture SKYCellflu Quadrivalent prefilled syringe are kept frozen and “banked.” Cell banking assures an adequate supply of cells is readily available for vaccine production. Growing the influenza viruses in cell culture for the manufacture of SKYCellflu Quadrivalent prefilled syringe is not dependent on an egg supply.
SKYCellflu Quadrivalent prefilled syringe contains no preservative or antibiotics.